#United States #Palatin Technologies #Princeton #MC4R #Nasdaq PTN

Palatin Technologies to Report First Quarter Fiscal Year 2027 Results

Palatin Technologies, Inc., traded on Nasdaq under the ticker symbol PTN, is gearing up to disclose its operating results for the first quarter of fiscal year 2027. This important announcement is scheduled for November 17, 2026, taking place before the opening of United States financial markets. Investors and analysts alike are keenly anticipating this report, which is likely to provide insights into the company's recent performance and future prospects.

On the same day, Palatin plans to host a conference call and live audio webcast, set to commence at 11:00 AM ET. This session will feature an update from the executive management team, covering corporate activities and development milestones. Such updates are crucial as they provide stakeholders with a comprehensive understanding of the company’s strategic direction and ongoing projects.

Key Details of the Upcoming Announcement

• - Press Release Timing: First quarter fiscal year 2027 operating results will be released at 7:30 AM ET on November 17, 2026.
• - Conference Call Participation:

- US Toll-Free Dial-In Number: 1-888-506-0062
- International Dial-In Number: 1-973-528-0011
- Participant Access Code: 336522

• - Replay Access Details: After the live session, the conference call will be available for replay from November 17 through December 1, 2026. The US toll-free replay number will be 1-877-481-4010, while international listeners can dial 1-919-882-2331. Use replay passcode 54837 to access the recorded materials.

The audio webcast, along with the replay, can be accessed through the 'Investors-Webcasts' section of Palatin’s official website, making it easy for interested parties to stay informed.

About Palatin Technologies

Palatin Technologies, Inc. is a biopharmaceutical company noted for its innovative approach in developing medicines that target the melanocortin receptor system. This system is pivotal in regulating various physiological functions, including energy homeostasis and metabolism.

The company focuses on advancing next-generation MC4R-selective agonists to address rare neuroendocrine obesity disorders. Some of these disorders include hypothalamic obesity, Prader-Willi syndrome, and Bardet-Biedl syndrome. Palatin is making headway in creating long-acting injectable peptide agonists, along with oral small-molecule agonists and a peptide agonist approach. Their objective is to ensure these treatments are both effective and tolerable, suitable for long-term management of these challenging conditions.

Furthermore, Palatin employs partnerships and licensing arrangements as strategic tools to propel its melanocortin-based programs forward. Such collaborations are essential as they allow the company to tap into additional expertise and resources, fostering innovation and accelerating the development process.

As the date of the announcement approaches, stakeholders should keep a close watch for the insights that Palatin will share, which may have significant implications for investors and patients alike. Given the company’s focus on cutting-edge solutions in the biopharmaceutical landscape, these results may set the tone for its market position moving forward.

In conclusion, Palatin Technologies stands at an anticipatory juncture as it prepares to share critical quarterly results and updates. The combination of strategic development in the biopharmaceutical realm and transparent communication during this period may help to bolster stakeholder confidence and clarify the company's trajectory in the healthcare landscape.